Jean-François Martini logo Pfizer logo

Jean-François Martini

Senior Director, Translational Oncology, Global Product Development-Oncology, Pfizer, Inc. (USA)


Jean-François Martini has over 17 years of biotech and pharma industry experience in pharmacology and translational sciences; he is currently Senior Director, Translational Oncology, Global Product Development-Oncology and has been at Pfizer, in La Jolla, California, since December 2011. He was previously Sr. Director, Translational Medicine, at Exelixis, South San Francisco, California. He completed his postdoctoral training at University of California, San Francisco where he studied the antiangiogenic properties of fragments of Prolactin and Growth Hormone, after obtaining a PhD in Biochemistry and Molecular Biology from University of Paris XI, France.

At Pfizer, he currently leads and/or oversees the translational strategy for palbociclib (Ibrance) in Breast Cancer and in other tumor types; the Renal Cell Cancer franchise (sunitinib and axitinib); crizotinib, and lorlatinib in Lung Cancer. He also leads the cross functional efforts in the area of liquid biopsy/cfDNA analysis, and represents Pfizer as part of the Cancer Moonshot, Blood Profiling Atlas-Cancer at the White House.

Jean-François Martini logo

Jean-François Martini

Senior Director, Translational Oncology, Global Product Development-Oncology, Pfizer, Inc. (USA)


Pfizer logo

Jean-François Martini has over 17 years of biotech and pharma industry experience in pharmacology and translational sciences; he is currently Senior Director, Translational Oncology, Global Product Development-Oncology and has been at Pfizer, in La Jolla, California, since December 2011. He was previously Sr. Director, Translational Medicine, at Exelixis, South San Francisco, California. He completed his postdoctoral training at University of California, San Francisco where he studied the antiangiogenic properties of fragments of Prolactin and Growth Hormone, after obtaining a PhD in Biochemistry and Molecular Biology from University of Paris XI, France.

At Pfizer, he currently leads and/or oversees the translational strategy for palbociclib (Ibrance) in Breast Cancer and in other tumor types; the Renal Cell Cancer franchise (sunitinib and axitinib); crizotinib, and lorlatinib in Lung Cancer. He also leads the cross functional efforts in the area of liquid biopsy/cfDNA analysis, and represents Pfizer as part of the Cancer Moonshot, Blood Profiling Atlas-Cancer at the White House.


Why WIN